Quantum Pharma “Revenue grew across all three divisions” Chris Rigg, Acting CEO

Chris Rigg, Chief Financial Officer and Acting Chief Executive Officer of Quantum Pharma LON:QP., commented:  “The core specials business is performing well and launches from the Niche Pharmaceuticals pipeline are being brought to market largely in line with plan.  The early indications are that sales of Glycopyrronium Bromide Oral Solution delivered under the core strategy of unlicensed to licensed and ‘cease and desist’ notifications are encouraging.

 

Following my appointment as Acting CEO in early August, we instigated and completed a review of a number of key areas of the business.

 

We found that the core specials business remains strong and cash generative and the potential still exists to deliver significant growth from our strong Niche Pharmaceuticals pipeline, including an exciting pipeline of unlicensed to licensed products where market data continues to support its potential sales value.  We believe that a simplified business, primarily focused on specials and the Group’s unlicensed to licensed growth platform offers the best opportunity for value creation.

 

Initial data from recent product launches indicates that generic, generic plus and medical device products are proving more challenging to take to market, leading us to conclude that more conservative sales assumptions are required for those types of products.  We have also taken a decision to commence consultation on the closure of our underperforming and loss making NuPharm business.

 

Although we continue to expect to deliver strong growth in the second half of the year and beyond, given the recent performance of products other than unlicensed to licensed products and the conclusions of the business review, the Board now expects performance will be materially below market expectations.  The Board is confident in the growth potential of the business from this revised base with its renewed focus on our key strategic objectives.”

Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, has today published its half year results for the six months to 31 July 2016 (‘H1-FY17’ or the ‘period’). Comparative data relates to the six months to 31 July 2015 (‘H1-FY16’) unless indicated otherwise.

 

Financial Highlights

 

(£ in millions except where stated)

H1-FY17

H1-FY16

Revenue

42.8

34.3

Gross profit

13.3

13.1

Adjusted EBITDA1

4.2

5.5

Operating profit

1.2

3.2

Profit before tax

0.8

2.8

Adjusted profit before tax1

2.6

4.5

Basic EPS

0.8 pence

2.0 pence

Adjusted EPS1

2.2 pence

3.2 pence

Development expenditure

2.3

3.0

Net debt

23.8

24.2

1 Excludes share based payments, one-off costs, acquisition costs and deferred consideration (treated as remuneration) for acquisitions.

 

 

·   Revenue grew across all three divisions; with the strongest advance coming from Medication Adherence (£5.9 million increase), which made a small contribution to gross profit.

·    On a like-for-like basis the Group is trading in line with performance for H1-FY16, having increased the cost base of Colonis by £1.2 million for market delivery related costs in the period as recent launches enter the market. In addition Nupharm, acquired in July 2015, has suffered losses of around £0.5 million and utilised £0.7 million of provision for rectification works in the period.

·    Development expenditure decreased as a result of the cost benefit of Lamda’s in-house development capability and a more focused and cost controlled development programme.

·     Net debt position was well managed across H1-FY17.

·     Strong working capital management across the period has enabled positive operational cash flows.

 

Business Highlights:

·    The core Specials division performed well during the period.

·     New five-year contract extension signed with AAH Pharmaceuticals Limited (“AAH”), the UK’s leading pharmaceutical wholesaler, which also benefits from the supply to an additional 281 Sainsbury’s in-store pharmacies acquired by Lloyds Pharmacy.

·    Niche Pharmaceuticals division launched five products, including expansion of the Vitamin D range with colecalciferol and ergocalciferol capsules, and two further products in the Mucodis® range of medical devices.

·    Launch timings largely in line with management expectations and products are now moving into the market access and sales delivery phase.

·     Appointment of Chris Rigg as CFO in March 2016.

 

Post Period End Highlights:

  ·  Launch of Glycopyrronium Bromide Oral Solution 1mg/5ml for the treatment of peptic ulcers, an  important unlicensed-to-licensed product for the Group.

·  Appointment of Chris Rigg as acting CEO in August 2016.

 

Business Review

·  Following his appointment as acting CEO, Chris Rigg initiated a review of key areas of the business.

·  This review has now been concluded, and its findings are as follows:

The core specials business remains strong and cash generative.

Market data continues to support the value of the Group’s unlicensed to licensed pipeline.

A simplified business, primarily focused on specials and the Group’s unlicensed to licensed growth platform, offers the best opportunity for value creation.

Generic, generic plus and medical device products are proving more challenging to take to market and more conservative sales assumptions are required for those products.

o  Decision taken to commence consultation on closure of the underperforming and loss making NuPharm business.

Further opportunities exist to reduce the Group’s cost base.

A lower level of net debt would help to support the further growth of the refocused business.

 

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Quantum Pharma Plc

    More articles like this

    Quantum Pharma Plc

    Quantum Pharma Plc FY17 Results – A Year of Change

    Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical developer and supplier to the health and care sectors, has reported its Preliminary financial results for the 12 months to January 31, 2017. Net sales grew by 28%

    Quantum Pharma Plc

    Quantum Pharma PLC makes strategic financial appointment

    County Durham based Quantum Pharma has bolstered its executive team with the help of business advisers UNW. The niche pharmaceutical developer and manufacturer, which supplies a range of innovative products to wholesalers, retailers and hospitals, approached

    Quantum Pharma Plc

    Quantum Pharma reduces debt after taking strategic action

    Niche pharma firm Quantum Pharma says it is on target to meet market expectations after taking action to tighten its focus. The Burnopfield pharmaceutical developer , manufacturer and supplier issued a trading update for the year

    Quantum Pharma Plc

    Quantum Pharma PLC Pre-close trading update – on plan

    Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has released a pre-close trading update this morning. Zeus Capital said: The Board has indicated that adjusted EBITDA

    Quantum Pharma Plc

    Quantum Pharma Plc CFO purchases shares in the PLC

    Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that on 3 January 2017 the Company was notified that Gerard Murray, Quantum’s Chief Financial Officer

    DirectorsTalk

    Quantum Pharma Plc “A good first half year”

    Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has today given DirectorsTalk its half year results for the six months to 31 July 2015,